Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. lifted its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 1.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 49,468,637 shares of the company's stock after purchasing an additional 467,196 shares during the quarter. Vanguard Group Inc. owned about 10.03% of Elanco Animal Health worth $737,083,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of ELAN. Norges Bank purchased a new position in Elanco Animal Health during the 4th quarter worth approximately $62,510,000. Dimensional Fund Advisors LP raised its position in Elanco Animal Health by 33.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 15,095,179 shares of the company's stock worth $224,920,000 after buying an additional 3,816,514 shares during the last quarter. Ancora Advisors LLC purchased a new position in Elanco Animal Health during the 3rd quarter worth approximately $37,189,000. Primecap Management Co. CA raised its position in Elanco Animal Health by 2.9% during the 4th quarter. Primecap Management Co. CA now owns 50,600,324 shares of the company's stock worth $753,945,000 after buying an additional 1,431,665 shares during the last quarter. Finally, Wolf Hill Capital Management LP purchased a new position in Elanco Animal Health during the 4th quarter worth approximately $20,683,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Elanco Animal Health news, Director William F. Doyle bought 15,000 shares of the stock in a transaction on Tuesday, May 21st. The shares were bought at an average price of $16.98 per share, with a total value of $254,700.00. Following the purchase, the director now directly owns 76,330 shares in the company, valued at approximately $1,296,083.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.57% of the stock is currently owned by corporate insiders.

Elanco Animal Health Price Performance

Elanco Animal Health stock traded down $0.15 during trading on Friday, reaching $18.05. The company had a trading volume of 3,896,886 shares, compared to its average volume of 3,344,120. The firm's 50-day simple moving average is $16.13 and its 200 day simple moving average is $15.58. Elanco Animal Health Incorporated has a 1-year low of $8.52 and a 1-year high of $18.80. The firm has a market capitalization of $8.92 billion, a PE ratio of -6.81, a price-to-earnings-growth ratio of 1.76 and a beta of 1.45. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.96 and a current ratio of 3.29.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.08. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. The company had revenue of $1.21 billion for the quarter, compared to analysts' expectations of $1.18 billion. During the same quarter in the previous year, the company posted $0.45 EPS. The firm's quarterly revenue was down 4.1% on a year-over-year basis. As a group, equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ELAN has been the subject of several recent research reports. Barclays lifted their target price on shares of Elanco Animal Health from $19.00 to $23.00 and gave the company an "overweight" rating in a report on Thursday, May 9th. Piper Sandler reaffirmed a "neutral" rating and set a $19.00 target price (up from $18.00) on shares of Elanco Animal Health in a report on Monday, May 13th. Morgan Stanley lifted their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, February 27th. Finally, The Goldman Sachs Group lifted their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a "sell" rating in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $18.29.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.